These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35025539)

  • 1. A randomized controlled trial for identifying the most suitable treatment for depression based on patients' attachment orientation.
    Zilcha-Mano S; Goldstein P; Dolev-Amit T; Ben David-Sela T; Barber JP
    J Consult Clin Psychol; 2021 Dec; 89(12):985-994. PubMed ID: 35025539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the most suitable treatment for depression based on patients' attachment: study protocol for a randomized controlled trial of supportive-expressive vs. supportive treatments.
    Zilcha-Mano S; Dolev T; Leibovich L; Barber JP
    BMC Psychiatry; 2018 Nov; 18(1):362. PubMed ID: 30419875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying who benefits most from supportive versus expressive techniques in psychotherapy for depression: Moderators of within- versus between-individual effects.
    Zilcha-Mano S; Webb CA
    J Consult Clin Psychol; 2024 Mar; 92(3):187-197. PubMed ID: 38059944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiety comorbidities in patients with major depressive disorder: the role of attachment.
    Huang YC; Lee Y; Lin PY; Hung CF; Lee CY; Wang LJ
    Int J Psychiatry Clin Pract; 2019 Nov; 23(4):286-292. PubMed ID: 31464550
    [No Abstract]   [Full Text] [Related]  

  • 5. Attachment as moderator of treatment outcome in major depression: a randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy.
    McBride C; Atkinson L; Quilty LC; Bagby RM
    J Consult Clin Psychol; 2006 Dec; 74(6):1041-54. PubMed ID: 17154734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating patient-specific mechanisms of change in SET vs. EFT for depression: study protocol for a mechanistic randomized controlled trial.
    Zilcha-Mano S; Shahar B; Fisher H; Dolev-Amit T; Greenberg LS; Barber JP
    BMC Psychiatry; 2021 Jun; 21(1):287. PubMed ID: 34078324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult attachment as a moderator of treatment outcome for generalized anxiety disorder: Comparison between cognitive-behavioral therapy (CBT) plus supportive listening and CBT plus interpersonal and emotional processing therapy.
    Newman MG; Castonguay LG; Jacobson NC; Moore GA
    J Consult Clin Psychol; 2015 Oct; 83(5):915-925. PubMed ID: 26052875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anxious attachment improves and is predicted by anxiety sensitivity in internet-based, guided self-help cognitive behavioral treatment for panic disorder.
    Zalaznik D; Strauss AY; Halaj A; Fradkin I; Ebert DD; Andersson G; Huppert JD
    J Couns Psychol; 2022 Mar; 69(2):211-221. PubMed ID: 34410764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between individuals with fearful-avoidant adult attachment orientation and early neural responses to emotional content: An event-related potentials (ERPs) study.
    Dan O; Zreik G; Raz S
    Neuropsychology; 2020 Feb; 34(2):155-167. PubMed ID: 31682140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explicit and implicit attachment and the outcomes of acceptance and commitment therapy and cognitive behavioral therapy for depression.
    A-Tjak JGL; Morina N; Boendermaker WJ; Topper M; Emmelkamp PMG
    BMC Psychiatry; 2020 Apr; 20(1):155. PubMed ID: 32264845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' individual differences in implicit and explicit expectations from the therapist as a function of attachment orientation.
    Zilcha-Mano S; Dolev-Amit T; Fisher H; Ein-Dor T; Strauß B
    J Couns Psychol; 2021 Nov; 68(6):682-695. PubMed ID: 34180691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attachment impacts cortisol awakening response in chronically depressed individuals.
    Adams GC; Wrath AJ; von Dewitz B; Marciniuk K; Roesler A; Napper S
    Psychoneuroendocrinology; 2020 Oct; 120():104778. PubMed ID: 32585509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel examination of atypical major depressive disorder based on attachment theory.
    Levitan RD; Atkinson L; Pedersen R; Buis T; Kennedy SH; Chopra K; Leung EM; Segal ZV
    J Clin Psychiatry; 2009 Jun; 70(6):879-87. PubMed ID: 19422755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electroacupuncture plus moxibustion therapy for patients with major depressive disorder: study protocol for a randomized controlled trial.
    Kim M; Choi EJ; Kim SP; Kim JE; Park HJ; Kim AR; Seo BN; Kwon OJ; Cho JH; Chung SY; Kim JH
    Trials; 2017 Jan; 18(1):16. PubMed ID: 28086934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attachment-based compassion therapy and adapted mindfulness-based stress reduction for the treatment of depressive, anxious and adjustment disorders in mental health settings: a randomised controlled clinical trial protocol.
    Montero-Marin J; Collado-Navarro C; Navarro-Gil M; Lopez-Montoyo A; Demarzo M; Herrera-Mercadal P; Barcelo-Soler A; Garcia-Campayo J
    BMJ Open; 2019 Oct; 9(10):e029909. PubMed ID: 31597650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of St John's wort in major depression: a randomized controlled trial.
    Shelton RC; Keller MB; Gelenberg A; Dunner DL; Hirschfeld R; Thase ME; Russell J; Lydiard RB; Crits-Cristoph P; Gallop R; Todd L; Hellerstein D; Goodnick P; Keitner G; Stahl SM; Halbreich U
    JAMA; 2001 Apr; 285(15):1978-86. PubMed ID: 11308434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interpersonal psychotherapy from research to practice].
    Rahioui H; Blecha L; Bottai T; Depuy C; Jacquesy L; Kochman F; Meynard JA; Papeta D; Rammouz I; Ghachem R
    Encephale; 2015 Apr; 41(2):184-9. PubMed ID: 24709225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.